The Novo-backed osteoporosis drug developer has now raised $35m in its series B round, and almost $100m in debt and equity since it was founded.
US-based biotechnology company Tarsa Therapeutics has concluded a second tranche of its series B round, raising an additional $7m from returning investors including Denmark based pharmaceutical firm Novo.
Novo was joined by venture capital firms Foresite Capital, MVM Life Science Partners, and Quaker Partners. Tarsa raised $28m in the first tranche of the round in March 2012.
Founded in 2009, Tarsa is currently developing Ostora, a calcitonin-based medical tablet for the treatment and prevention of postmenopausal osteoporosis.
The company recently…
